Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-06

AUTHORS

E. Barrett-Connor, S. W. Wade, T. P. Do, S. Satram-Hoang, R. Stewart, G. Gao, D. Macarios

ABSTRACT

Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up. More... »

PAGES

733-741

References to SciGraph publications

  • 2005-03-03. Correlation between patient recall of bone densitometry results and subsequent treatment adherence in OSTEOPOROSIS INTERNATIONAL
  • 2005-04. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study in AGING CLINICAL AND EXPERIMENTAL RESEARCH
  • 2010-01-26. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ in OSTEOPOROSIS INTERNATIONAL
  • 2009-12-05. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis in OSTEOPOROSIS INTERNATIONAL
  • 2009-06-05. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review in OSTEOPOROSIS INTERNATIONAL
  • 2008-07-08. Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications in OSTEOPOROSIS INTERNATIONAL
  • 2009-08-06. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass in OSTEOPOROSIS INTERNATIONAL
  • 2006-08-01. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey in OSTEOPOROSIS INTERNATIONAL
  • 2006-03-15. Determinants of adherence to osteoporosis treatment in clinical practice in OSTEOPOROSIS INTERNATIONAL
  • 2008-09-12. Patient Decision to Initiate Therapy for Osteoporosis: The Influence of Knowledge and Beliefs in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2004-02-26. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2003-03. Tolerability and compliance with risedronate in clinical practice in OSTEOPOROSIS INTERNATIONAL
  • 2009-12-10. Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice in TRIALS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3

    DOI

    http://dx.doi.org/10.1007/s00198-011-1620-3

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1049583566

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/21625886


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bone Density Conservation Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diphosphonates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Epidemiologic Methods", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Medication Adherence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Osteoporosis, Postmenopausal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Osteoporotic Fractures", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Patient Satisfaction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Primary Health Care", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United States", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.266100.3", 
              "name": [
                "Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Barrett-Connor", 
            "givenName": "E.", 
            "id": "sg:person.01346631166.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346631166.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Wade Outcomes Research and Consulting, Salt Lake City, UT, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Wade Outcomes Research and Consulting, Salt Lake City, UT, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wade", 
            "givenName": "S. W.", 
            "id": "sg:person.0617012057.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Do", 
            "givenName": "T. P.", 
            "id": "sg:person.0733051777.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Satram-Hoang", 
            "givenName": "S.", 
            "id": "sg:person.01262457746.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262457746.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stewart", 
            "givenName": "R.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gao", 
            "givenName": "G.", 
            "id": "sg:person.01151363702.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151363702.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Macarios", 
            "givenName": "D.", 
            "id": "sg:person.0652405653.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652405653.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1477-7525-2-12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039428500", 
              "https://doi.org/10.1186/1477-7525-2-12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-008-0674-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041206509", 
              "https://doi.org/10.1007/s00198-008-0674-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03324587", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038551591", 
              "https://doi.org/10.1007/bf03324587"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-006-0166-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034510225", 
              "https://doi.org/10.1007/s00198-006-0166-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-0976-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025143605", 
              "https://doi.org/10.1007/s00198-009-0976-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11606-008-0772-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029719812", 
              "https://doi.org/10.1007/s11606-008-0772-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-004-1818-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019683703", 
              "https://doi.org/10.1007/s00198-004-1818-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1133-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042711530", 
              "https://doi.org/10.1007/s00198-009-1133-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-002-1370-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021711183", 
              "https://doi.org/10.1007/s00198-002-1370-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1745-6215-10-113", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051078892", 
              "https://doi.org/10.1186/1745-6215-10-113"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1134-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021804673", 
              "https://doi.org/10.1007/s00198-009-1134-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1023-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034744843", 
              "https://doi.org/10.1007/s00198-009-1023-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-006-0073-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020337646", 
              "https://doi.org/10.1007/s00198-006-0073-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2011-04-06", 
        "datePublishedReg": "2011-04-06", 
        "description": "Women in POSSIBLE US\u2122 who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US\u2122) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n\u2009=\u20091,182; median\u2009=\u200987.5 (Q1\u2009=\u200975.0, Q3\u2009=\u2009100.0)] and lowest for global satisfaction [n\u2009=\u20092,340; median\u2009=\u200964.0 (Q1\u2009=\u200955.7, Q3\u2009=\u200977.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI\u2009=\u20090.63\u20130.85; effectiveness 0.82, 95% CI\u2009=\u20090.70\u20130.97; and global satisfaction 0.73, 95% CI\u2009=\u20090.63\u20130.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR\u2009=\u20090.60, 95% CI\u2009=\u20090.37\u20130.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1\u00a0year of follow-up.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00198-011-1620-3", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1100834", 
            "issn": [
              "0937-941X", 
              "1433-2965"
            ], 
            "name": "Osteoporosis International", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "keywords": [
          "treatment satisfaction", 
          "severe side effects", 
          "discontinuation/", 
          "osteoporosis medications", 
          "side effects", 
          "hazard ratio", 
          "study entry", 
          "Prospective Observational Scientific Study", 
          "osteoporosis medication adherence", 
          "discontinuation/switching", 
          "global satisfaction domains", 
          "side effect severity", 
          "Treatment Satisfaction Questionnaire", 
          "lower treatment satisfaction", 
          "proportional hazards regression", 
          "greater treatment satisfaction", 
          "longitudinal cohort study", 
          "patient-reported data", 
          "TSQM scores", 
          "postmenopausal women", 
          "cohort study", 
          "medication adherence", 
          "osteoporosis therapy", 
          "hazards regression", 
          "lifestyle behaviors", 
          "medications", 
          "effect severity", 
          "logistic regression", 
          "median score", 
          "satisfaction questionnaire", 
          "satisfaction domains", 
          "women", 
          "global satisfaction", 
          "high satisfaction", 
          "lower scores", 
          "risk", 
          "scores", 
          "lower satisfaction", 
          "association", 
          "bisphosphonates", 
          "regression", 
          "satisfaction", 
          "therapy", 
          "MethodsData", 
          "follow", 
          "experience study", 
          "study", 
          "severity", 
          "adherence", 
          "period", 
          "effect", 
          "questionnaire", 
          "entry", 
          "participants", 
          "compliance", 
          "years", 
          "scientific studies", 
          "persistence", 
          "possible uses", 
          "uses", 
          "data", 
          "relationship", 
          "ratio", 
          "results", 
          "instruction", 
          "domain", 
          "behavior", 
          "switching", 
          "side effect experience influence osteoporosis medication adherence", 
          "effect experience influence osteoporosis medication adherence", 
          "experience influence osteoporosis medication adherence", 
          "influence osteoporosis medication adherence", 
          "postmenopausal osteoporosis (PMO) medications", 
          "PMO medications", 
          "Observational Scientific Study", 
          "Bone Loss Experience (POSSIBLE US\u2122) Study", 
          "Loss Experience (POSSIBLE US\u2122) Study", 
          "self-reported discontinuation/switching", 
          "pharmacologic PMO medications", 
          "ResultsMedian TSQM scores", 
          "patient-reported side effect severity", 
          "ConclusionsLower treatment satisfaction"
        ], 
        "name": "Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US\u2122", 
        "pagination": "733-741", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1049583566"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00198-011-1620-3"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "21625886"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00198-011-1620-3", 
          "https://app.dimensions.ai/details/publication/pub.1049583566"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:27", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_552.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00198-011-1620-3"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'


     

    This table displays all metadata directly associated to this object as RDF triples.

    299 TRIPLES      22 PREDICATES      135 URIs      114 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00198-011-1620-3 schema:about N1605d65b29b34b508494ca7aaa4f26b3
    2 N2b1f4dcb92eb4a45ac6c8ae1bcee5ffc
    3 N38bf9e369cad4dba928e030461910058
    4 N3d397fb614854766ace7be7f140b7660
    5 N45be1e26e95749bc84901e8989b712cf
    6 N56a56b664f4a44b79521605e003fb02c
    7 N860c980081b1420c98101071b935162f
    8 N9b0fbcd760534c739ab989e606cb54d8
    9 Nad92fa1762904f49b0fcaea30b5276e0
    10 Nb50406031aba49ee8070a1d50cf0da1f
    11 Nbfaf76ca0dde4a88bc1d048217f44940
    12 Ndd3ad5c20a6c4a2191f6ec66e4f91a26
    13 Ne157d56714ec48d69aef7fd7bb5787df
    14 Nf33e5d0c317043d096c78c753d706f01
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N2be2513a968747b6b03a899ebbbccba9
    18 schema:citation sg:pub.10.1007/bf03324587
    19 sg:pub.10.1007/s00198-002-1370-3
    20 sg:pub.10.1007/s00198-004-1818-8
    21 sg:pub.10.1007/s00198-006-0073-6
    22 sg:pub.10.1007/s00198-006-0166-2
    23 sg:pub.10.1007/s00198-008-0674-3
    24 sg:pub.10.1007/s00198-009-0976-0
    25 sg:pub.10.1007/s00198-009-1023-x
    26 sg:pub.10.1007/s00198-009-1133-5
    27 sg:pub.10.1007/s00198-009-1134-4
    28 sg:pub.10.1007/s11606-008-0772-0
    29 sg:pub.10.1186/1477-7525-2-12
    30 sg:pub.10.1186/1745-6215-10-113
    31 schema:datePublished 2011-04-06
    32 schema:datePublishedReg 2011-04-06
    33 schema:description Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up.
    34 schema:genre article
    35 schema:inLanguage en
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N20832a543b7046919751dd63e6e04dc1
    38 N35ca7b7153c24961a3208389e759c980
    39 sg:journal.1100834
    40 schema:keywords Bone Loss Experience (POSSIBLE US™) Study
    41 ConclusionsLower treatment satisfaction
    42 Loss Experience (POSSIBLE US™) Study
    43 MethodsData
    44 Observational Scientific Study
    45 PMO medications
    46 Prospective Observational Scientific Study
    47 ResultsMedian TSQM scores
    48 TSQM scores
    49 Treatment Satisfaction Questionnaire
    50 adherence
    51 association
    52 behavior
    53 bisphosphonates
    54 cohort study
    55 compliance
    56 data
    57 discontinuation/
    58 discontinuation/switching
    59 domain
    60 effect
    61 effect experience influence osteoporosis medication adherence
    62 effect severity
    63 entry
    64 experience influence osteoporosis medication adherence
    65 experience study
    66 follow
    67 global satisfaction
    68 global satisfaction domains
    69 greater treatment satisfaction
    70 hazard ratio
    71 hazards regression
    72 high satisfaction
    73 influence osteoporosis medication adherence
    74 instruction
    75 lifestyle behaviors
    76 logistic regression
    77 longitudinal cohort study
    78 lower satisfaction
    79 lower scores
    80 lower treatment satisfaction
    81 median score
    82 medication adherence
    83 medications
    84 osteoporosis medication adherence
    85 osteoporosis medications
    86 osteoporosis therapy
    87 participants
    88 patient-reported data
    89 patient-reported side effect severity
    90 period
    91 persistence
    92 pharmacologic PMO medications
    93 possible uses
    94 postmenopausal osteoporosis (PMO) medications
    95 postmenopausal women
    96 proportional hazards regression
    97 questionnaire
    98 ratio
    99 regression
    100 relationship
    101 results
    102 risk
    103 satisfaction
    104 satisfaction domains
    105 satisfaction questionnaire
    106 scientific studies
    107 scores
    108 self-reported discontinuation/switching
    109 severe side effects
    110 severity
    111 side effect experience influence osteoporosis medication adherence
    112 side effect severity
    113 side effects
    114 study
    115 study entry
    116 switching
    117 therapy
    118 treatment satisfaction
    119 uses
    120 women
    121 years
    122 schema:name Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™
    123 schema:pagination 733-741
    124 schema:productId N05cb11aee67b47da840bbd9c8de087ce
    125 N4b8f616c978c4350aea894c2c5122fda
    126 Ne545252e5d364dc083a74232055c6691
    127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049583566
    128 https://doi.org/10.1007/s00198-011-1620-3
    129 schema:sdDatePublished 2022-01-01T18:27
    130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    131 schema:sdPublisher Ne42720fb167b41aba661e754cd4ccf35
    132 schema:url https://doi.org/10.1007/s00198-011-1620-3
    133 sgo:license sg:explorer/license/
    134 sgo:sdDataset articles
    135 rdf:type schema:ScholarlyArticle
    136 N04f8ef42e9b947a298026dc20491e6ac schema:affiliation grid-institutes:grid.417886.4
    137 schema:familyName Stewart
    138 schema:givenName R.
    139 rdf:type schema:Person
    140 N05cb11aee67b47da840bbd9c8de087ce schema:name pubmed_id
    141 schema:value 21625886
    142 rdf:type schema:PropertyValue
    143 N1605d65b29b34b508494ca7aaa4f26b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Diphosphonates
    145 rdf:type schema:DefinedTerm
    146 N20832a543b7046919751dd63e6e04dc1 schema:issueNumber 2
    147 rdf:type schema:PublicationIssue
    148 N2b1f4dcb92eb4a45ac6c8ae1bcee5ffc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Primary Health Care
    150 rdf:type schema:DefinedTerm
    151 N2be2513a968747b6b03a899ebbbccba9 rdf:first sg:person.01346631166.35
    152 rdf:rest N40c095edbbb34ff09e408f3e2f2f980a
    153 N35ca7b7153c24961a3208389e759c980 schema:volumeNumber 23
    154 rdf:type schema:PublicationVolume
    155 N38bf9e369cad4dba928e030461910058 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Treatment Outcome
    157 rdf:type schema:DefinedTerm
    158 N3d397fb614854766ace7be7f140b7660 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Bone Density Conservation Agents
    160 rdf:type schema:DefinedTerm
    161 N40c095edbbb34ff09e408f3e2f2f980a rdf:first sg:person.0617012057.00
    162 rdf:rest Nb60ea90026ec433f9d25dbb1940c5bdf
    163 N45be1e26e95749bc84901e8989b712cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Epidemiologic Methods
    165 rdf:type schema:DefinedTerm
    166 N49d2df2814574d389da9a7137f7f3f4d rdf:first sg:person.01262457746.85
    167 rdf:rest Nc3f717041254441a9e117084972c0c62
    168 N4b8f616c978c4350aea894c2c5122fda schema:name dimensions_id
    169 schema:value pub.1049583566
    170 rdf:type schema:PropertyValue
    171 N56a56b664f4a44b79521605e003fb02c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Female
    173 rdf:type schema:DefinedTerm
    174 N5eecbc65c86f46e09b1cfa8320bca800 rdf:first sg:person.0652405653.55
    175 rdf:rest rdf:nil
    176 N6900f4dc8aaf4bf6b959bf931bf7b4bb rdf:first sg:person.01151363702.27
    177 rdf:rest N5eecbc65c86f46e09b1cfa8320bca800
    178 N860c980081b1420c98101071b935162f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Osteoporotic Fractures
    180 rdf:type schema:DefinedTerm
    181 N9b0fbcd760534c739ab989e606cb54d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Medication Adherence
    183 rdf:type schema:DefinedTerm
    184 Nad92fa1762904f49b0fcaea30b5276e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name United States
    186 rdf:type schema:DefinedTerm
    187 Nb50406031aba49ee8070a1d50cf0da1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Patient Satisfaction
    189 rdf:type schema:DefinedTerm
    190 Nb60ea90026ec433f9d25dbb1940c5bdf rdf:first sg:person.0733051777.39
    191 rdf:rest N49d2df2814574d389da9a7137f7f3f4d
    192 Nbfaf76ca0dde4a88bc1d048217f44940 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Aged
    194 rdf:type schema:DefinedTerm
    195 Nc3f717041254441a9e117084972c0c62 rdf:first N04f8ef42e9b947a298026dc20491e6ac
    196 rdf:rest N6900f4dc8aaf4bf6b959bf931bf7b4bb
    197 Ndd3ad5c20a6c4a2191f6ec66e4f91a26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Humans
    199 rdf:type schema:DefinedTerm
    200 Ne157d56714ec48d69aef7fd7bb5787df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Osteoporosis, Postmenopausal
    202 rdf:type schema:DefinedTerm
    203 Ne42720fb167b41aba661e754cd4ccf35 schema:name Springer Nature - SN SciGraph project
    204 rdf:type schema:Organization
    205 Ne545252e5d364dc083a74232055c6691 schema:name doi
    206 schema:value 10.1007/s00198-011-1620-3
    207 rdf:type schema:PropertyValue
    208 Nf33e5d0c317043d096c78c753d706f01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Middle Aged
    210 rdf:type schema:DefinedTerm
    211 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    212 schema:name Medical and Health Sciences
    213 rdf:type schema:DefinedTerm
    214 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    215 schema:name Clinical Sciences
    216 rdf:type schema:DefinedTerm
    217 sg:journal.1100834 schema:issn 0937-941X
    218 1433-2965
    219 schema:name Osteoporosis International
    220 schema:publisher Springer Nature
    221 rdf:type schema:Periodical
    222 sg:person.01151363702.27 schema:affiliation grid-institutes:grid.417886.4
    223 schema:familyName Gao
    224 schema:givenName G.
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151363702.27
    226 rdf:type schema:Person
    227 sg:person.01262457746.85 schema:affiliation grid-institutes:grid.417886.4
    228 schema:familyName Satram-Hoang
    229 schema:givenName S.
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262457746.85
    231 rdf:type schema:Person
    232 sg:person.01346631166.35 schema:affiliation grid-institutes:grid.266100.3
    233 schema:familyName Barrett-Connor
    234 schema:givenName E.
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346631166.35
    236 rdf:type schema:Person
    237 sg:person.0617012057.00 schema:affiliation grid-institutes:None
    238 schema:familyName Wade
    239 schema:givenName S. W.
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
    241 rdf:type schema:Person
    242 sg:person.0652405653.55 schema:affiliation grid-institutes:grid.417886.4
    243 schema:familyName Macarios
    244 schema:givenName D.
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652405653.55
    246 rdf:type schema:Person
    247 sg:person.0733051777.39 schema:affiliation grid-institutes:grid.417886.4
    248 schema:familyName Do
    249 schema:givenName T. P.
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39
    251 rdf:type schema:Person
    252 sg:pub.10.1007/bf03324587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038551591
    253 https://doi.org/10.1007/bf03324587
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1007/s00198-002-1370-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021711183
    256 https://doi.org/10.1007/s00198-002-1370-3
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1007/s00198-004-1818-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019683703
    259 https://doi.org/10.1007/s00198-004-1818-8
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
    262 https://doi.org/10.1007/s00198-006-0073-6
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1007/s00198-006-0166-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034510225
    265 https://doi.org/10.1007/s00198-006-0166-2
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1007/s00198-008-0674-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041206509
    268 https://doi.org/10.1007/s00198-008-0674-3
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1007/s00198-009-0976-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025143605
    271 https://doi.org/10.1007/s00198-009-0976-0
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1007/s00198-009-1023-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034744843
    274 https://doi.org/10.1007/s00198-009-1023-x
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1007/s00198-009-1133-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042711530
    277 https://doi.org/10.1007/s00198-009-1133-5
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1007/s00198-009-1134-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021804673
    280 https://doi.org/10.1007/s00198-009-1134-4
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1007/s11606-008-0772-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029719812
    283 https://doi.org/10.1007/s11606-008-0772-0
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1186/1477-7525-2-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039428500
    286 https://doi.org/10.1186/1477-7525-2-12
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1186/1745-6215-10-113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051078892
    289 https://doi.org/10.1186/1745-6215-10-113
    290 rdf:type schema:CreativeWork
    291 grid-institutes:None schema:alternateName Wade Outcomes Research and Consulting, Salt Lake City, UT, USA
    292 schema:name Wade Outcomes Research and Consulting, Salt Lake City, UT, USA
    293 rdf:type schema:Organization
    294 grid-institutes:grid.266100.3 schema:alternateName Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA
    295 schema:name Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA
    296 rdf:type schema:Organization
    297 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., Thousand Oaks, CA, USA
    298 schema:name Amgen Inc., Thousand Oaks, CA, USA
    299 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...